Reply letter to "safety of SARS-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance". Issue 11 (2nd November 2021)

• Record Type: Journal Article
• Authors: Saborido-Fiaño, Rebeca; Martinón-Torres, Nazareth; Crujeiras-Martinez, Vanesa; Couce, Maria Luz; Leis, Rosaura
• Is Part Of: Human vaccines & immunotherapeutics. Volume 17:Issue 11(2021)
• Page Start: 4115
• Page End: 4116
• Publication Date: 2021-11-02
• Subjects: SARS-Cov 2; vaccine; Hereditary fructose intolerance; children; sucrose; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2021.1959149
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: In the letter, Urro et al. performed a search on the sucrose, fructose and sorbitol content in the approved Sars-Cov-2 vaccines and they concluded that these vaccines can be safely administered in adults affected by Hereditary fructose intolerance. The Pfizer-BioNTech COVID-19 Vaccine is currently approved for use in adolescents ≥ 12 years and the Moderna COVID-19 vaccine is close to approval for use in children over 12 years of age. Furthermore, both vaccines have initiated clinical trials that will include infant as young as 6 months. Therefore, we considerate important to analyze the safely administration of this two vaccines in children with Hereditary fructose intolerance.